5α-reductase Inhibitors: Finasteride and Dutasteride in Feminising Therapy

Evidence Note

What is the question?

Other androgen-directed drugs work by lowering the body’s testosterone production, blocking the androgen receptor, or both. Finasteride and dutasteride do neither. They block a single downstream step: the conversion of testosterone into dihydrotestosterone (DHT), an androgen with stronger activity than testosterone in several skin, hair and genital tissues, much of it formed locally in those tissues. So the question is narrow but important — does blocking that step add anything to a feminising regimen, and if not, when is one still worth taking? (It’s about adults on feminising hormones; the companion review grades the full evidence.)

What does the evidence say?

Suppressing testosterone leaves less raw material to convert. DHT is made from testosterone. If your regimen has already driven testosterone low, there’s less of it being converted — so a large added effect from blocking that conversion becomes less likely. But no one has actually measured tissue DHT during feminising treatment, and no trial has tested whether adding one of these drugs changes how you feminise; the most careful appraisal calls the added benefit “unclear,” rather than proven small.

They can nudge your testosterone number up, not down. Because they block a route testosterone would otherwise take, the number in your blood can rise modestly in some people after you start. A rise like that doesn’t by itself mean the drug has failed — but a testosterone level that remains above the intended range still needs interpreting in the context of the whole regimen — including dose, absorption, adherence and treatment goals — rather than being waved away. The drug doesn’t lower testosterone directly; it blocks the conversion to DHT.

Their clearest use is confirmed androgenetic hair loss. Male-pattern (androgenetic) hair loss is driven by DHT acting locally at the scalp, and serum testosterone alone doesn’t fully predict it — follicular sensitivity and local metabolism matter too — so a DHT blocker has a genuine rationale there. Three caveats, though. It’s a dermatological treatment, not a feminiser; the hair loss should first be confirmed as androgenetic, since thyroid problems, iron deficiency and other causes can mimic it; and the efficacy evidence is mostly from cisgender men. The two drugs aren’t interchangeable, either — finasteride has the clearer established hair-loss indication, while dutasteride lowers DHT more completely but is generally used off-label for hair and stays in the body far longer. The usual aim is to slow or stabilise further loss; regrowth is variable, often limited in advanced loss, and takes months to assess.

For other things — acne, oily skin, facial or body hair — there’s essentially no direct evidence that adding one helps in trans women whose testosterone is already suppressed. And established terminal facial hair generally needs electrolysis or laser hair reduction for durable removal or reduction; an anti-androgen isn’t a substitute.

The main guideline advises against routine feminising use. WPATH’s Standards of Care recommend against their routine use as part of feminising hormone therapy, because efficacy and safety data in trans people are lacking. Using finasteride for confirmed androgenetic hair loss is a separate dermatological decision.

How strong is the evidence?

Split it. The basic pharmacology, the fetal-development risk from exposure during pregnancy, and the effect on the PSA blood test are well established. The mood and sexual-effect signals are recognised by regulators, but uncertain in size and in how far they apply to trans women. And that these drugs add anything to feminisation once testosterone is suppressed is essentially unstudied — no trial, and a guideline that recommends against routine use. In short, we understand these drugs better than we can justify using them to feminise.

Where are the uncertainties?

The biggest is simply that no one has tested whether adding one changes any feminising outcome in trans women. The mood picture is unsettled too, and worth stating precisely: European regulators concluded that suicidal ideation should be listed as a side effect of finasteride tablets, with the frequency unknown; UK guidance also identifies depression and suicidal ideation as risks of finasteride and warns that sexual dysfunction may persist after stopping. Dutasteride carries precautionary class wording, but a causal association with suicidal ideation was not established in the European review. How large these risks actually are remains uncertain, and they haven’t been specifically studied in trans women. Separately, most (not all) trans women keep a prostate, and these drugs commonly reduce serum PSA by about half after sustained treatment — individual responses vary, and feminising hormones can lower it further — so any clinician interpreting a PSA result needs to know, because the usual adjustment rules haven’t been validated in trans women.

In feminising care these are best understood as a targeted treatment for scalp-hair loss — not a general feminiser.

What does this mean for practice?

If the goal is feminising, there’s no established benefit from adding one to a well-managed regimen of oestrogen and testosterone control, and the main guideline advises against routine use — a 5α-reductase inhibitor is not a substitute for getting that core regimen right. If the goal is confirmed androgenetic hair loss, they have a genuine rationale as a hair treatment, with clear eyes about the thin trans-specific evidence and the mood and sexual-effect warnings that now come with finasteride. And because fetal exposure can disrupt male external genital development, someone who is or may be pregnant should not handle crushed or broken finasteride tablets or leaking dutasteride capsules. Two things worth holding onto: don’t read a modest rise in your testosterone number as the drug failing — though a level that remains above the intended range still needs checking — and report any new or worsening low mood promptly. If you have suicidal thoughts or feel in immediate danger, seek urgent crisis or emergency help rather than waiting for a routine appointment. None of this is a reason to start or stop anything on your own — whether one of these drugs is right for you, and how it’s monitored, are decisions to make with your clinician.